Table 1. Table of experimental data obtained from the literature [5].
| Experiment | VPC fates (% 1°, 2°, 3°) | TD | VD | References | |||
|---|---|---|---|---|---|---|---|
| P4.p | P5.p | P6.p | |||||
| Fully penetrant phenotypes | |||||||
| (1) | Wild type | 0,0,100 | 0,100,0 | 100,0,0 | × | ||
| (2) | let-23 mosaic (No EGF receptors in P5/7.p) | Wild type | × | [13, 15] | |||
| (3) | Half dose of lin-3 (Half EGF ligand) | Wild type | × | [16] | |||
| (4) | Half dose of lin-12 (Half Notch receptor) | Wild type | × | [17] | |||
| (5) | Notch null, and 2 × WT EGF (2 ACs) | 0,0,100 | 100,0,0 | 100,0,0 | × | [17] | |
| (6) | No Notch signaling, WT EGF | 0,0,100 | 0,0,100 | 100,0,0 | × | [14, 18, 19] | |
| Excess EGF | |||||||
| (7) | JU1100 (overexpression of EGF ligand, level to fit) | 18,46,36 | 45.5,54.5,0 | 96,4,0 | × | [20] | |
| (8) | JU1107 (2.75 × WT EGF) | 2,15,83 | 19,81,0 | 100,0,0 | × | [21] | |
| Reduced Notch | [21] | ||||||
| (9) | JU2039 (WT EGF, reduced Notch) | 0,0,100 | 1,89,10 | 100,0,0 | × | ||
| (10) | JU2113 (1.25 × WT EGF, reduced Notch) | 4,6,90 | 18,70,12 | 100,0,0 | × | ||
| Excess EGF & ectopic Notch | [21] | ||||||
| (11) | JU2091 (1.25 × WT EGF, ectopic Notch) | 0,0,100 | 0,100,0 | 100,0,0 | × | ||
| (12) | JU2089 (1.79 × WT EGF, ectopic Notch) | 0,6,94 | 1,99,0 | 100,0,0 | × | ||
| (13) | JU2092 (2.75 × WT EGF, ectopic Notch) | 5,24,71 | 0,100,0 | 100,0,0 | × | ||
| Reduced EGF | [21] | ||||||
| (14) | CB1417 (lin-3(e1417) EGF hypomorph) | 0,0,100 | 1,99,0 | 54,0,46 | × | ||
| (15) | JU2095 (mild ectopic Notch × EGF hypomorph) | 0,1,99 | 0,15,85 | 72,0,28 | × | ||
| Phenotypes following anchor cell ablation | [22] | ||||||
| (16) | L2 lethargus | - | 0,0,100 | 0,0,100 | × | ||
| (17) | Early L3 | - | 1.5,21,77.5 | 18,18,64 | × | ||
| (18) | DU divided | - | 0,54.63,45.37 | 31,38,31 | × | ||
| (19) | VU divided | - | 4,90,6 | 52,48,0 | × | ||
| (20) | 3° divided | - | 1,99,0 | 65,35,0 | × | ||
| (21) | 2-cell stage | - | 1,99,0 | 93,7,0 | × | ||
Probabilities have been converted into percentages for clarity. Fates for P4.p and P8.p (or P5.p and P7.p) have been averaged, since we assume that the pattern is symmetrical around the AC, and P3.p is not considered in this study as it often does not divide and fuses with the hypodermis, assuming tertiary fate. Abbreviations: TD = training data; VD = validation data. Developmental stages: (L2 lethargus) lethargic L2; (Early L3) early L3; (DU divided) Dorsal Uterine precursor cells dividing or divided once; (VU divided) Ventral Uterine precursor cells dividing or divided once; (3° divided) 3° cells have divided; (2-cell stage) all Pn.p cells have divided once.